For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a
platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic …

Obesity and underweight are a growing health problem worldwide and a challenge for
clinicians concerning antithrombotic therapy, due to the associated risks of thrombosis …

Background After a brief period of dual antiplatelet therapy, P2Y12 inhibitor monotherapy in
the absence of aspirin effectively reduces bleeding without increasing recurrent ischemia in …

Background Optimal dual antiplatelet therapy (DAPT) duration in patients at high bleeding
risk (HBR) is not fully defined. We aimed to compare the safety and effectiveness of short …

Newer generation durable polymer drug-eluting stents (DP-DES) and biodegradable
polymer DES (BP-DES) have similar efficacy with dual-antiplatelet therapy (DAPT) duration …

Obesity and underweight are a growing health problem worldwide and a challenge for
clinicians concerning antithrombotic therapy, due to the associated risks of thrombosis …

Shortening the duration of dual-antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) was shown to be effective and safe in patients at high bleeding risk (HBR) …

Background. Current guidelines recommend the use of potent antiplatelet agents in patients
undergoing percutaneous coronary intervention (PCI) following an acute coronary syndrome …

Introduction The worldwide prevalence of chronic kidney disease (CKD) has significantly
increased in the past decades. Scientific reports have shown CKD to be an enhancing risk …

Background Although ticagrelor monotherapy after 3-month dual antiplatelet therapy (DAPT)
results in a significantly greater net clinical benefit over that with ticagrelor-based 12-month …